SWOG 1608 Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

June 29, 2018
https://clinicaltrials.gov/ct2/show/NCT03269669
Cancer - Lymphoma
Principal Investigator: Ding Wang, MD
LYMPHOMA, FOLLICULAR, RELAPSED, REFRACTORY, GRADE 1, GRADE 2, GRADE 3, CANCER
Accepting Participants